CD19 and acute lymphoblastic leukemia: FACS analysis of residual target cells at sacrifice revealed identical cytotoxic activity of both BT‐ or FTVII‐treated CD19‐CAR T cells in controlling NALM6 (Figure 3E), SEM (Figure 3F), and PDX B‐ALL (Figure 4C) cells in PB, BM, and spleen.